Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.
Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A. Young HL, et al. Among authors: flaherty kt. J Exp Med. 2017 Jun 5;214(6):1691-1710. doi: 10.1084/jem.20160855. Epub 2017 Apr 27. J Exp Med. 2017. PMID: 28450382 Free PMC article.
The MAPK pathway in melanoma.
Fecher LA, Amaravadi RK, Flaherty KT. Fecher LA, et al. Among authors: flaherty kt. Curr Opin Oncol. 2008 Mar;20(2):183-9. doi: 10.1097/CCO.0b013e3282f5271c. Curr Opin Oncol. 2008. PMID: 18300768 Review.
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. Johannessen CM, et al. Among authors: flaherty kt. Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24. Nature. 2010. PMID: 21107320 Free PMC article.
Targeting the RAS pathway in melanoma.
Ji Z, Flaherty KT, Tsao H. Ji Z, et al. Among authors: flaherty kt. Trends Mol Med. 2012 Jan;18(1):27-35. doi: 10.1016/j.molmed.2011.08.001. Epub 2011 Sep 30. Trends Mol Med. 2012. PMID: 21962474 Free PMC article. Review.
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. Poulikakos PI, et al. Among authors: flaherty kt. Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662. Nature. 2011. PMID: 22113612 Free PMC article.
BRAF inhibitors and melanoma.
Flaherty KT. Flaherty KT. Cancer J. 2011 Nov-Dec;17(6):505-11. doi: 10.1097/PPO.0b013e31823e5357. Cancer J. 2011. PMID: 22157295 Review.
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. Corcoran RB, et al. Among authors: flaherty kt. Cancer Discov. 2012 Mar;2(3):227-35. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16. Cancer Discov. 2012. PMID: 22448344 Free PMC article.
480 results